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Comparison of prostatic artery embolisation (PAE) versus  
transurethral resection of the prostate (TURP) for benign  
prostatic hyperplasia: randomised, open label, non-inferiority 
trial
Dominik Abt,1 Lukas Hechelhammer,2 Gautier Müllhaupt,1  Stefan Markart,2 Sabine Güsewell,3 
Thomas M Kessler,4 Hans-Peter Schmid,1 Daniel S Engeler,1 Livio Mordasini1
Abstract
Objective
To compare prostatic artery embolisation (PAE) with 
transurethral resection of the prostate (TURP) in the 
treatment of lower urinary tract symptoms secondary 
to benign prostatic hyperplasia in terms of patient 
reported and functional outcomes.
Design
Randomised, open label, non-inferiority trial.
Setting
Urology and radiology departments of a Swiss tertiary 
care centre.
Participants
103 patients aged ≥40 years with refractory lower 
urinary tract symptoms secondary to benign prostatic 
hyperplasia were randomised between 11 February 
2014 and 24 May 2017; 48 and 51 patients reached 
the primary endpoint 12 weeks after PAE and TURP, 
respectively.
Interventions
PAE performed with 250-400 μm microspheres under 
local anaesthesia versus monopolar TURP performed 
under spinal or general anaesthesia.
Main outcomes and measures
Primary outcome was change in international prostate 
symptoms score (IPSS) from baseline to 12 weeks 
after surgery; a difference of less than 3 points 
between treatments was defined as non-inferiority 
for PAE and tested with a one sided t test. Secondary 
outcomes included further questionnaires, functional 
measures, magnetic resonance imaging findings, and 
adverse events; changes from baseline to 12 weeks 
were compared between treatments with two sided 
tests for superiority.
Results
Mean reduction in IPSS from baseline to 12 weeks 
was −9.23 points after PAE and −10.77 points after 
TURP. Although the difference was less than 3 points 
(1.54 points in favour of TURP (95% confidence 
interval −1.45 to 4.52)), non-inferiority of PAE could 
not be shown (P=0.17). None of the patient reported 
secondary outcomes differed significantly between 
treatments when tested for superiority; IPSS also did 
not differ significantly (P=0.31). At 12 weeks, PAE 
was less effective than TURP regarding changes in 
maximum rate of urinary flow (5.19 v 15.34 mL/s; 
difference 10.15 (95% confidence interval −14.67 to 
−5.63); P<0.001), postvoid residual urine (−86.36 v 
−199.98 mL; 113.62 (39.25 to 187.98); P=0.003), 
prostate volume (−12.17 v −30.27 mL; 18.11 (10.11 
to 26.10); P<0.001), and desobstructive effectiveness 
according to pressure flow studies (56% v 93% shift 
towards less obstructive category; P=0.003). Fewer 
adverse events occurred after PAE than after TURP (36 
v 70 events; P=0.003).
Conclusions
The improvement in lower urinary tract symptoms 
secondary to benign prostatic hyperplasia seen 12 
weeks after PAE is close to that after TURP. PAE is 
associated with fewer complications than TURP but 
has disadvantages regarding functional outcomes, 
which should be considered when selecting patients. 
Further comparative study findings, including longer 
follow-up, should be evaluated before PAE can be 
considered as a routine treatment.
Trial registration
Clinicaltrials.gov NCT02054013.
Introduction
Benign prostatic hyperplasia is one of the most common 
diseases in men and is often associated with bladder 
outlet obstruction and lower urinary tract symptoms. 
The incidence of benign prostatic hyperplasia in men 
aged 50-60 years is 50% and rises with increasing 
age.1 Treatment for the disease incurs a substantial 
economic burden, with estimated annual costs of 
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WhAt Is AlreAdy knoWn on thIs topIc
Prostatic artery embolisation (PAE) for the treatment of benign prostatic 
hyperplasia has been introduced into clinical practice without high level 
evidence, and is now increasingly performed worldwide
Available PAE data point to promising outcomes, including a favourable safety 
profile
Only three trials so far have included a control group receiving established 
surgical treatments for benign prostatic hyperplasia; all studies performed so 
far have been criticised for methodological drawbacks and have shown highly 
contradictory results
WhAt thIs study Adds
An improvement in symptoms close to that achieved by transurethral resection of 
the prostate (TURP) was found after PAE in the short term
An inferior desobstructive effect and a favourable side effect profile were found 
for PAE, and should be considered for patient selection
Further comparative study findings (including longer follow-up periods) should 
be evaluated before PAE can be considered as a routine treatment
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up to US$4 billion (£3.01bn; €3.45bn) in the United 
States in 2006, and mean annual treatment costs of 
€858 per patient in Europe in 2003.2 3 Owing to the 
demographic shift towards an elderly population, 
costs arising from lower urinary tract symptoms 
secondary to benign prostatic hyperplasia (BPH-LUTS) 
are likely to increase substantially. Surgical treatment 
is recommended if conservative treatment fails or for 
patients with complications related to benign prostatic 
hyperplasia, and is performed in more than 100 000 
men annually in the USA.4 Transurethral resection of 
the prostate (TURP) is still the surgical gold standard 
in most patients.5 6 However, it is associated with high 
morbidity,7 8 and 40% of patients have residual lower 
urinary tract symptoms that require drug treatment 
within five years after surgery.9 These drawbacks have 
led to a continuous search for less invasive treatments.
Improvements in BPH-LUTS after prostatic artery 
embolisation (PAE)—a minimally invasive procedure 
that can be performed under local anaesthesia—were 
first reported in 2000.10 Since then, nearly 1000 
cases have been published, showing significant 
improvements in BPH-LUTS, a favourable side effect 
profile, and lower treatment costs than with TURP.11 
12 Considering these advantages, non-inferiority of 
PAE compared with TURP as a reference treatment 
would support its implementation as a treatment 
for BPH-LUTS. However, all studies performed so far 
have been criticised for methodological drawbacks; 
only three trials have included a control group that 
received established surgical treatments for benign 
prostatic hyperplasia, and the results were highly 
contradictory.13-15
The discussion regarding the use of PAE to treat 
BPH-LUTS is highly controversial and is influenced 
by political interests, as a fundamental domain of 
urologists is challenged by interventional radiologists. 
Evidence to support the use of PAE in the treatment 
of BPH-LUTS is so far insufficient, and PAE is still 
considered experimental.11 16 The lack of high quality 
evidence comparing PAE and TURP is a crucial 
knowledge gap in urology. We therefore compared 
the efficacy and safety of the two interventions in a 
randomised, open label, non-inferiority trial.
Methods
Trial design
This investigator initiated, open label, single centre, 
randomised controlled trial was performed with the 
close collaboration of the departments of urology 
and radiology at St Gallen Cantonal Hospital, 
Switzerland. The trial was designed by the lead 
investigators and supported by biostatisticians from 
the hospital’s clinical trials unit. The study protocol 
was reviewed by experts from the clinical trials 
unit and approved by the local ethics committee 
(EKSG14/004). The study was funded by a grant from 
the hospital’s research committee (14/08), and had 
no commercial support. Independent experts from 
the clinical trials unit performed study coordination, 
data management, and data and safety monitoring. 
SecuTrial (Interactive Systems) was used for electronic 
trial data management. The clinical trials unit’s 
statistician (SG) performed the data analyses. Trained 
study physicians collected patient information and 
undertook enrolment and randomisation. The trial was 
performed according to the World Medical Association 
Declaration of Helsinki17 and the Guidelines for Good 
Clinical Practice.18 The study protocol was published19 
and registered at ClinicalTrials.gov (NCT02054013).
Participants
The trial aimed to recruit a population with refractory 
BPH-LUTS that is typically treated with TURP in 
everyday clinical practice. Inclusion criteria were men 
aged at least 40 years, TURP indicated, refractory 
to medical treatment or not willing to undergo or 
continue medical treatment, with a prostate size 25-80 
mL as measured by transabdominal ultrasound, with 
an international prostate symptoms score (IPSS) of at 
least 8, with an IPSS related quality of life of at least 
3 points, with a maximum urinary flow rate of less 
than 12 mL/s or urinary retention, and who provided 
written informed consent.
Exclusion criteria were severe atherosclerosis, 
aneurysmatic changes or severe tortuosity in the 
aortic bifurcation or internal iliac arteries, acontractile 
detrusor, neurogenic lower urinary tract dysfunction, 
urethral stenosis, bladder diverticulum, bladder stone, 
allergy to intravenous contrast media, contraindication 
for magnetic resonance imaging, pre-interventionally 
proven carcinoma of the prostate, and renal failure 
(glomerular filtration rate <60 mL/min).
Interventions
PAE was performed by an experienced interventional 
radiologist (LH) who was familiar with the procedure. 
A 16 F transurethral catheter was inserted before 
surgery. A unilateral femoral sheath was placed in the 
right common femoral artery under local anaesthesia. 
The prostatic arterial supply was identified by selective 
internal iliac arteriography by a 5 F angiocatheter 
(Merit Medical). Prostatic arteries were selectively 
catheterised with 1.9-2.4 F microcatheters (Parkway 
soft; Asahi Intecc; Progreat; Terumo; Direxion; 
Boston Scientific) and embolised by use of 250-400 
μm Embozene microspheres (Boston Scientific). Cone 
beam computed tomography was applied to identify 
prostatic arteries or prevent off-target embolisation 
in patients with challenging anatomical conditions.20 
PAE was performed according to established 
techniques, bilaterally if possible,21-23 and was 
considered successful in the absence of the normal 
blush of the prostate and complete stasis of flow in the 
prostate arteries on angiography after embolisation. 
The transurethral catheter was removed the morning 
after the intervention.
Monopolar TURP was performed under spinal or 
general anaesthesia by an experienced study physician 
(DA, H-PS, DSE, or LM) using a 24 F resectoscope (Karl 
Storz Endoskope) with a cutting power of 180 W and a 
coagulation power of 60 W, a standard tungsten wire 
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loop, and electrolyte free mannitol-sorbitol solution 
(Purisole, Fresenius Kabi AG). Technical conduct 
of TURP adhered to generally accepted standards 
described elsewhere,24 and was performed step by 
step for the middle lobe, lateral lobes, ventral part, 
and apical residual tissue with the surgical capsule of 
the prostate serving as a landmark. A 20 F three way 
catheter was inserted for irrigation after resection, and 
left for at least two days depending on postoperative 
haematuria.
All patients received perioperative antibiotic 
prophylaxis, which was discontinued after removal 
of the bladder catheter or after three days at the 
latest (ciprofloxacin 500 mg twice daily). An anti-
inflammatory (diclofenac 75 mg twice daily) and acid 
suppressant (pantoprazole 40 mg once daily) were 
administered for one week. Prostatic drug treatments 
were discontinued on the day of TURP and two weeks 
after PAE (owing to supposed slower efficacy).
Outcomes
Data were collected before intervention (baseline), 
during participants’ stay in hospital, and at three 
scheduled follow-up visits at one, six, and 12 weeks 
after surgery. The primary outcome was the change 
from baseline to 12 weeks in the self administered IPSS 
questionnaire score, with scores ranging from 0 to 35 
points (≤7: mild symptoms, 8-19: moderate symptoms, 
≥20 points: severe symptoms).25 Secondary endpoints 
were assessed at scheduled visits and comprised:
•	 Free uroflowmetry
•	 Postvoid residual urine assessed by 
transabdominal ultrasound 
•	 Quality of life related to lower urinary tract 
symptoms (ranging from 0 (“delighted”) to 6 
(“terrible”))
•	 Questionnaire chronic prostatitis symptoms index 
(CPSI) that assesses pain, voiding, and quality of 
life (score ranging from 0 (best) to 43 (worst))
•	 International index of erectile function short form 
5 (IIEF) (score ranging from 0 (worst) to 25 (best))
•	 Blood tests for haemoglobin and prostate specific 
antigen
•	 Bladder diaries
•	 Assessment of adverse events according to 
the modified Clavien system26 and common 
terminology criteria for adverse events.27
Prostate volume assessment using magnetic 
resonance imaging (BiopSee 2.2, Medcom) and pressure 
flow studies according to the standards recommended 
by the International Continence Society28 were 
performed at the baseline and 12 week visits. During 
the participants’ stay in hospital, postoperative pain 
was assessed on a visual analogue scale (ranging 
from 0 (no pain) to 10 (maximum pain)). Assessment 
of procedural parameters included operation time, 
weight of resected tissue (for TURP), success of 
embolisation (monolateral or bilateral), and radiation 
dose (for PAE). Questionnaires were completed in the 
absence of the physician before visits. All patients with 
indwelling bladder catheters at baseline were asked to 
complete baseline questionnaires on the basis of their 
situation before catheter insertion (longest bladder 
catheter indwelling time before IPSS assessment was 
two weeks).
Additional secondary outcomes included changes 
in inflammatory blood parameters (eg, cytokines) and 
magnetic resonance imaging based analyses of tissue 
vascularisation after PAE. These secondary outcomes 
will be analysed in separate publications.
Sample size and statistical methods
Data analysis was performed per protocol.The study 
was designed as a non-inferiority trial with respect 
to the primary endpoint: the change in IPSS from 
baseline to 12 weeks. A change in IPSS of 3.0 points has 
previously been shown to be perceived by patients as a 
“slight improvement” only. Therefore, we considered a 
difference in mean IPSS change between both groups 
smaller than 3 points as showing non-inferiority 
for PAE.25 Based on previous findings,29 a standard 
deviation of 4.6 was expected for the change in IPSS. 
Thus, if the true mean difference was 0, a one sided t 
test with a significance level of 0.025 would have 80% 
power to reject the null hypothesis that PAE was inferior 
to TURP, with a sample size of 38 patients per group. 
Assuming a dropout rate of 20% during long term 
follow-up, we therefore aimed to include 100 patients.
The change in IPSS between baseline and 12 weeks 
was compared between groups by a one sided t test for 
the non-inferiority of PAE, with a significance level of 
0.025. An additional analysis of the primary outcome 
was adjusted for IPSS at baseline by use of analysis 
of covariance. Secondary endpoints were treated as 
standard superiority comparisons, and means and 95% 
confidence intervals at baseline and each follow-up 
visit are reported. We compared changes from baseline 
to follow-up visits between treatment groups with two 
sided t tests for non-equality of means. All reported 
statistics were calculated from the available data. 
Thus, occasional missing values for some secondary 
outcomes cause the mean change from baseline to a 
follow-up visit (reported in text) to differ slightly from 
the difference between mean values at individual time 
points (reported in figures). 
Mann-Whitney U tests were used instead of t tests 
for ordinal endpoints with less than 10 levels and for 
numerical endpoints that were clearly not normally 
distributed. We compared the overall frequency 
of adverse events in the two treatment groups to 
frequencies expected from patient numbers in the two 
groups with an exact binomial test. Relative frequencies 
of particular safety outcomes were compared between 
treatment groups with two sided tests for non-equality 
of proportions.
Randomisation
We performed randomisation using the data 
management software SecuTrial, stratifying for patient 
age (<70 or ≥70 years) and prostate volume (<50 or ≥50 
mL) through minimisation. SecuTrial was programmed 
by the clinical trials unit’s data manager, and automatic 
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treatment allocation by SecuTrial was determined for 
individual patients without a predefined sequence 
after inclusion and entry of baseline characteristics by 
the investigators.
Patient involvement
No patients were involved in setting the research 
question, trial design, outcome measures, or 
recruitment of the study. Patients will be informed by 
press reports and the hospital’s homepage following 
this publication.
results
Study patients
The distribution of patients at screening, 
randomisation, treatment, and follow-up is shown 
in the CONSORT flowchart (fig 1). Of 144 patients 
assessed for eligibility, 41 were excluded because 
they did not meet inclusion criteria (n=22), declined 
to participate (n=15), or for other reasons (n=4). Thus, 
103 patients were randomly assigned to PAE or TURP 
between 11 February 2014 and 24 May 2017. Two 
patients allocated to PAE and one allocated to TURP 
refused to undergo surgery after randomisation and 
were excluded from the study. PAE was not possible due 
to vascular disorders in one patient, who underwent 
laser vapourisation of the prostate subsequently and 
was also excluded from the analysis. All 48 patients 
receiving PAE and 51 patients receiving TURP were 
available for the 12 week follow-up visit that included 
the primary outcome assessment. None needed an 
indwelling bladder catheter at this time. Patient 
characteristics and demographic data are provided in 
table 1.
Primary endpoint
Both treatments improved BPH-LUTS similarly. The 
mean change in IPSS from baseline to 12 weeks was 
−9.23 points after PAE and −10.77 points after TURP, 
and the difference of 1.54 points in favour of TURP 
was not significant (P=0.31; fig 2A). Non-inferiority of 
PAE (difference between means <3 points) could still 
not be established, owing to the large variation among 
individual outcomes (95% confidence interval for 
mean difference −1.45 to 4.52 points, P=0.17 for test 
for non-inferiority; fig 2B).
A baseline adjusted analysis of covariance of the 
primary endpoint showed a mean difference between 
treatments of 2.87 points in favour of TURP (95% 
confidence interval 0.53 to 5.21; P=0.46 for test for 
non-inferiority of PAE).
Secondary endpoints
Perioperative data and recovery parameters are shown 
in table 2. Compared with PAE, procedural time was 
statistically significantly shorter for TURP, but PAE 
showed favourable results in terms of blood loss, 
bladder catheter indwelling time, and duration of 
hospital stay.
In accordance with the IPSS, changes from baseline 
to 12 weeks did not differ statistically significantly 
for all other patient reported outcomes after PAE 
and TURP. IPSS related quality of life improved by 
−2.33 points after PAE and −2.69 points after TURP 
(difference 0.35 in favour of TURP (95% confidence 
interval –0.30 to 1.00); P=0.15; fig 2C). The chronic 
prostatitis symptoms index improved by −7.83 points 
versus −7.16 points (difference 0.67 in favour of PAE 
(−3.65 to −2.32); P=0.66; fig 2D). The international 
index of erectile function changed by −0.98 points 
versus −1.84 points (difference 0.87 in favour of PAE 
(−1.89 to 3.63); P=0.53; fig 2E).
By contrast, functional outcomes after 12 weeks 
were clearly in favour of TURP. After PAE and TURP, we 
saw an improvement in maximum rates of free urinary 
flow by 5.19 mL/s versus 15.34 mL/s (difference 10.15 
in favour of TURP (95% confidence interval −14.67 
to −5.63); P<0.001; fig 3A) and changes in postvoid 
residual urine by −86.36 mL versus −199.98 mL 
(difference 113.62 in favour of TURP (39.25 to 187.98); 
P=0.003; fig 3B). A marked initial increase in prostate 
specific antigen after PAE largely vanished after 12 
weeks, leading to reductions by 2.00 μg/L versus 
3.11 μg/L (difference 1.11 in favour of TURP (−0.89 
to 3.10); P=0.07; fig 3C). The mean change in prostate 
volume as measured by magnetic resonance imaging 
volumetry from baseline to 12 weeks after PAE and 
TURP was −12.17 mL versus −30.27 mL (difference 
18.11 in favour of TURP (10.11 to 26.10); P<0.001; 
fig 3D). Pressure flow studies showed significant 
disadvantages for PAE compared with TURP for the 
reduction of bladder outlet obstruction, indicated by 
a change in detrusor pressure at maximum urinary 
flow rate of −17.17 cm H2O versus −41.07 cm H2O 
(difference 23.91 in favour of TURP (9.09 to 38.72); 
P=0.002; fig 3E) and a shift towards a less obstructive 
category in 56% of patients after PAE and 93% after 
TURP (proportion test, P=0.003; fig 3F).
Bladder diaries showed functional improvements 
from baseline to 12 weeks without significant 
Allocated to TURP (n=52):
  Received allocated intervention (n=51)
  Did not receive allocated intervention (n=1):
    Declined TURP (n=1)
Allocated to PAE (n=51):
  Received allocated intervention (n=48)
  Did not receive allocated intervention (n=3):
    Declined PAE (n=2)
    PAE not possible bilaterally (n=1)
Lost to follow-up (n=0)Lost to follow-up (n=0)
Assessed for eligibility (n=144)
Randomised (n=103)
Analysed (n=48)
Excluded from analysis (n=0)
Analysed (n=51)
Excluded from analysis (n=0)
Excluded (n=41):
  Not meeting inclusion criteria (n=22)
    Rejected due to vascular disorders (n=5)
  Declined to participate (n=15)
  Other reasons (n=4)
Fig 1 | Study enrolment and randomisation (CONSORT flow diagram)
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differences between PAE and TURP. Mean voided 
volume increased by 28.7 mL versus 18.9 mL 
(difference 9.8 in favour of PAE (95% confidence 
interval −38.94 to 58.54); P=0.69), daytime frequency 
of urination decreased by 0.75 versus 0.89 (difference 
0.14 in favour of TURP (−1.08 to 1.37); P=0.81), and 
nocturia decreased by 0.35 versus 0.21 (difference 
0.14 in favour of PAE (−0.83 to 0.55); P=0.68).
Safety
Figure 4 shows the frequency of particular types of 
adverse events. Treatment related adverse events were 
half as frequent after PAE than after TURP during the 
first 12 weeks of the study (n=36 v n=70; P=0.003; fig 
4). The risk of at least one treatment related adverse 
event did not differ significantly between groups 
(62.5% v 70.6%, relative risk after PAE 0.89 (95% 
confidence interval 0.67 to 1.17), P=0.52), but fewer 
patients had two or more treatment related adverse 
events after PAE than after TURP (16.7% v 45.1%, 
0.37 (0.18 to 0.75), P=0.005). The distribution of 
adverse events among severity classes26 was similar 
for both treatments (P=0.44). Clavien grades 1, 2, and 
3 were assigned to 71.4%, 22.9%, and 5.7% of the 
adverse events after PAE, respectively and to 64.5%, 
24.2%, and 11.3% of the adverse events after TURP, 
respectively.
Postoperative pain was reported by more patients 
after PAE than after TURP (56.3% v 31.9%, relative risk 
1.76 (95% confidence interval 1.08 to 2.87); P=0.03). 
Among patients who reported pain, the maximum pain 
intensity tended to be higher after PAE than after TURP 
(mean score on visual analogue scale 4.0 v 3.1), but the 
difference (0.9 points (95% confidence interval 0.76 to 
2.42)) was not significant (P=0.28). Severe pain (≥6 
points on visual analogue scale) was experienced by 
nine (18.8%) patients after PAE and two (4.3%) after 
TURP (relative risk 4.41 (95% confidence interval 1.00 
to 19.33); P=0.06), but was limited to the first 12-24 
hours after the procedure.
Complications specific to angiointerventions (that 
is, endovascular interventions) were limited to one 
patient with moderate haematoma at the puncture 
site, one with postembolisation syndrome including 
fever (lasting <24 h), and one with ischaemia in a 
limited area of the bladder wall requiring transurethral 
removal of necrotic tissue. One patient reported de 
novo erectile dysfunction despite the use of highly 
selective embolisation, and 56% (14/25) of patients 
in whom ejaculation was assessable had ejaculatory 
dysfunction after PAE compared with 84% (21/25) 
after TURP (relative risk 0.67 (95% confidence interval 
0.45 to 0.98); P=0.06).
discussion
Principal findings
This randomised trial provides reliable comparative 
data that enhance the so far inconsistent and low 
quality evidence available for PAE,11 and outlines 
its advantages and disadvantages compared with 
TURP. Our results indicate that similar degrees of 
improvement in symptoms are achieved with PAE 
and TURP in the short term, although PAE has slightly 
smaller improvements than TURP. However, clear 
advantages of TURP over PAE were found regarding 
the pure desobstructive effect, reflected in improved 
micturition parameters and a reduction in bladder 
outlet obstruction.
Surgery for benign prostatic hyperplasia is usually 
performed for refractory symptoms associated with 
reduced quality of life; thus, patient reported outcomes 
are generally considered the most representative 
primary outcome.5 In this regard, both TURP and PAE 
have yielded effect sizes in the improvement of BPH-
LUTS defined as “marked” elsewhere.25 Nevertheless, 
TURP has a more pronounced, pure urodynamic 
Table 1 | Baseline characteristics of study patients with lower urinary tract symptoms secondary to benign prostatic 
hyperplasia, according to received intervention*
Characteristic PAE (n=48) TURP (n=51)
Age (years) 65.7 (9.3) 66.1 (9.8)
Body mass index† 26.5 (4.2) 27.0 (3.9)
Charlson comorbidity index 3.6 (1.6) 4.3 (2.1)
IPSS 19.38 (6.37) 17.59 (6.17)
Prostate specific antigen concentration (μg/L) 4.2 (5.4) 4.5 (5.6)
Prostate volume (mL)
 Measured by transabdominal ultrasound 51.2 (16.5) 52.1 (18.6)
 Measured by magnetic resonance imaging 52.8 (32.0) 56.5 (31.1)
Medical treatment of lower urinary tract symptoms before surgery (No (%) of patients)
 5α-reductase inhibitors 0 1 (2.0)
 α1-adrenergic receptor antagonists 26 (54.2) 22 (43.1)
 Combination of both drugs mentioned above 14 (29.2) 13 (25.5)
 Antimuscarinic drugs 8 (16.7) 9 (17.6)
 Total No receiving drug treatment 41 (85.4) 44 (86.3)
Indwelling urethral catheter at baseline (No (%) of patients) 9 (18.8) 12 (24.5)
Data are mean (standard deviation) unless indicated otherwise. IPSS=international prostate symptoms score; PAE=prostatic artery embolisation; 
TURP=transurethral resection of the prostate.
*Baseline symptom scores other than IPSS, micturition parameters, and urodynamic findings are reported in figure 2 and figure 3.
†Body mass index calculated as weight in kilograms divided by height squared in metres.
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desobstructive effect than PAE. Thus, TURP should be 
preferred in patients with complications associated 
with bladder outlet obstruction, such as repeated 
acute urinary retention, bladder diverticula or 
stones, impaired renal function due to bladder outlet 
obstruction, and weak detrusor pressure combined 
with high amounts of postvoid residual urine (although 
some of these patients were excluded from our study).
PAE
TURP
IP
SS
A
Preop 1 week 6 weeks 12 weeks
P=0.03
P=0.67 P=0.31
19.38
17.59
14.93
9.31
10.64
8.25
10.15
6.82
0
5
10
15
20
25
PAE
TURP
IP
SS
-Q
oL
C
Preop 1 week 6 weeks 12 weeks
4.00
4.24
3.22
1.73
2.06
2.12
1.67
1.55
0
1
2
3
4
5
PAE
TURP
CP
SI
 sc
or
e
D
Preop 1 week 6 weeks 12 weeks
15.38
14.32
14.40
11.34
9.04
11.08
7.54
7.36
0
5
10
15
20
0
5
10
15
20
IP
SS
 ch
an
ge
 fr
om
 b
as
el
in
e 
to
 1
2 
we
ek
s B
PAE
Mean change
-9.23 points
TURP
Mean change
-10.77 points
Dierence PAE - TURP = 1.5 points
(95% CI −1.45 to 4.52), P=0.17
-30
-40
-20
-10
0
10
20
PAE
TURP
IIE
F s
co
re
E
Preop 1 week 6 weeks 12 weeks
15.15
13.10
12.74
9.18
13.79
9.73
14.64
11.67
PAE
TURP
P<0.001
P=0.53
P=0.15
P=0.80
P=0.16 P=0.53
P=0.28
P=0.04
P=0.66
Fig 2 | Primary outcome and patient reported secondary outcomes in patients with lower urinary tract symptoms 
secondary to benign prostatic hyperplasia receiving prostatic artery embolisation (PAE) or transurethral resection 
of the prostate (TURP). (A) Improvements in the international prostate symptom score (IPSS) after PAE and TURP. (B) 
Mean difference in IPSS (primary efficacy endpoint) between treatment groups. Secondary endpoints between PAE and 
TURP for (C) IPSS related quality of life (QoL); (D) chronic prostatitis symptoms index (CPSI) assessing pain, urinary 
symptoms, and quality of life; and (E) international index of erectile function (IIEF). I bars in (A, C, D, E) indicate 95% 
confidence intervals. Boxes in (B) show the interquartile range, with central lines indicating the median. Each whisker 
extends to the most extreme data point, which deviates no more than 1.5 times the interquartile range from the box. 
Points indicate observations, which lie beyond the extremes of the whiskers. Preop=before the operation (that is, 
baseline). P values (apart from part B) are reported for differences of change from baseline between both treatments. 
Means are calculated from the complete dataset at each visit. Occasional missing values for parts (D) and (E) cause 
slight differences between the mean change from baseline to a follow-up visit and the difference between mean values 
at individual time points reported in the text
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The apparent contradiction between patient 
reported and functional outcomes can be explained by 
the poor correlation between urodynamic obstruction 
and subjective perception of symptoms described 
previously,30 and the fact that storage symptoms—
which improve less than voiding symptoms after 
conventional surgery—are usually more bothersome 
to patients.30-32 Similar findings have been reported 
for other minimally invasive procedures such 
as transurethral needle ablation or microwave 
thermotherapy of the prostate and were associated 
with higher reintervention rates.33 34 In our study, 
considerably fewer and less severe adverse events 
were found after PAE, which could be performed under 
local anaesthesia and was associated with reduced 
blood loss and shorter duration of hospital stay and 
catheterisation than TURP.
Strengths and weaknesses of the study
Strengths of the study included its interdisciplinary 
study setting and the independent trial monitoring 
and data management. The study population and 
outcomes after TURP were similar to large series of 
real world data on TURP published previously and our 
results seem to represent clinical routine.7 Moreover, 
the study followed up all patients treated according to 
randomisation, and provided a detailed investigation 
of adverse events.
Our study has some limitations. The number 
of patients was not high enough to conclusively 
determine non-inferiority or inferiority of PAE 
versus TURP, despite the difference between the two 
procedures being less than the defined threshold of 3 
IPSS points. Non-inferiority could not be demonstrated 
conclusively in the primary analysis because variability 
of the change in IPSS among patients in both groups 
(standard deviation 7.5) was larger than the value of 
4.6 assumed in the sample size calculation. A main 
cause for this discrepancy might have been different 
inclusion criteria and patient characteristics in the 
study taken as a basis.29 In addition, the difference 
between PAE and TURP in the additional baseline 
adjusted analysis was only slightly below 3 points (that 
is, 2.87; P=0.46 for non-inferiority), which further 
outlines a need for larger scale trials.
With our study design, treatment groups might not 
have been perfectly balanced with respect to prognostic 
factors other than the two stratifying factors—for 
example, the degree of obstruction or comorbidities. 
However, separate analyses with adjustment for all 
these factors showed that they were unrelated to 
our primary outcome (change in IPSS) and did not 
influence test results for differences between PAE and 
TURP.
Blinding of patients and physicians was not feasible 
in the framework of our trial. Therefore, both patients 
and physicians might have been biased in favour of 
or against a new treatment. Expert bias cannot be 
excluded, because one interventional radiologist 
performed all embolisations. The evaluation of patient 
satisfaction during mid-term and long term follow-up 
will be crucial because of a potential placebo effect, 
the fact that TURP might be more bothersome than PAE 
in the first 12 weeks, and the possibility of a further 
treatment effect beyond 12 weeks after PAE. Moreover, 
the significant difference between both treatments 
with regard to desobstruction might lead to higher 
reintervention rates after PAE over the long term.
Strengths and weaknesses in relation to other 
studies
Evidence regarding the efficacy and safety of PAE in the 
treatment of BPH-LUTS has mainly been based on proof-
of-concept trials and cohort studies so far, and the three 
published trials providing comparative data have had 
substantial methodological limitations.11 While Russo 
and colleagues compared PAE with open prostatectomy 
in a matched pair non-randomised study,14 Carnevale 
and colleagues15 randomised only 30 patients to PAE 
or TURP. The trial15 was not registered, and did not 
report on a clearly defined primary outcome measure. 
The largest randomised controlled study published 
so far by Gao and colleagues13 has been questioned 
by the opinion leaders in the field of PAE because of 
major inconsistencies, including a limited adherence 
to fundamental standards of scientific practice, under-
reporting of adverse events, and an “over-reporting” of 
the results of PAE.35
So far, little has been reported on PAE associated 
complications, and a higher complication rate for 
PAE than for TURP in pooled analyses of comparative 
trials was attributed to substantial under-reporting 
of complications after TURP.8 11 Our results elucidate 
Table 2 | Perioperative data and recovery parameters in patients with lower urinary 
tract symptoms secondary to benign prostatic hyperplasia receiving prostatic artery 
embolisation (PAE) or transurethral resection of the prostate (TURP) 
Measure PAE (n=48) TURP (n=51) P
Anaesthesia 
General (No (%) of patients) — 26 (51) —
Spinal (No (%) of patients) — 25 (49) —
Local (No (%) of patients) 48 (100) — —
Procedure time (min) 122.2 (25.8) 69.5 (22.5) <0.001
PAE procedure details 
Bilateral (No (%) of patients) 36 (75.0) — —
Unilateral (No (%) of patients) 12 (25.0) — —
Fluoroscopy time (min) 50.8 (17.5) — —
Dose area product (Gy/cm2) 176.5 (101.2) — —
Pain during intervention (visual analogue scale) 0.1 (0.6) — —
Additional analgesics needed (No (%) of patients)* 2 (4.2) — —
Amount of embolisation particles used (mL) 1.0 (0.4) — —
TURP procedure details
Time of resection (min) — 58.25 (24.33) —
Weight of resected tissue (g) — 25.20 (15.16) —
Retrieval rate (g/min) — 0.43 (0.20) —
Recovery parameters
Preoperative haemoglobin (g/L) 147.4 (12.2) 145.2 (12.7) 0.38
Haemoglobin decrease 24h (g/L) −4.3 (7.0) −13.8 (11.0) 0.001
Bladder catheter indwelling time (days) 1.3 (1.4) 3.3 (1.4) 0.001
Duration of hospital stay (days) 2.2 (0.6) 4.2 (1.7) 0.001
Data are mean (standard deviation) unless stated otherwise.
*1 g of paracetamol given as premedication.
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these issues and illustrate that the scope of adverse 
events after PAE—although favourable compared 
to TURP—has also been underestimated so far. 
Preservation of ejaculatory function is a fundamental 
aspect for many patients and has to be discussed 
before any treatment is initiated. Ejaculatory disorders 
have so far been reported in only two of more than 
1000 cases in the literature,11 but were encountered 
in our series in 56% of patients receiving PAE; this 
finding was unexpected and needs clarification in the 
future.
Although duration of hospital stay and catheterisation 
are practice dependent and were handled rather 
conservatively after TURP in this trial, PAE has been 
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Fig 3 | Functional secondary outcome parameters in patients with lower urinary tract symptoms secondary to benign 
prostatic hyperplasia receiving prostatic artery embolisation (PAE) or transurethral resection of the prostate (TURP). 
Parameters include (A) maximum urinary flow rate, (B) postvoid residual urine, (C) concentrations of prostate specific 
antigen (PSA), (D) Prostate volume reduction as assessed by magnetic resonance imaging, (E) desobstruction as 
measured by detrusor pressure at maximum flow rate (PdetQmax), and (F) urodynamic obstruction as measured 
by International Continence Society (ICS) classification. I bars=95% confidence intervals; dots=means calculated 
from the complete dataset at each visit. P values are reported for differences of change from baseline between both 
treatments. Preop=before the operation (that is, baseline); postop=after the operation. Occasional missing values for 
secondary outcomes may cause the mean change from baseline to a follow-up visit in (parts A-E) to differ slightly from 
the difference between mean values at individual time points reported in the text
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shown to be feasible even without catheterisation 
and in an outpatient setting.36 Radiation exposure 
of the patients receiving PAE was clearly below the 
thresholds recommended for such interventions by the 
Swiss Federal Office of Public Health37 and the mean 
total dose area product in this study was less than half 
than in other studies,38 indicating that the potential to 
improve radiation protection during PAE is currently 
clearly not yet fully exploited.
Follow-up in the trials mentioned above was for 
up to two years. Although assessment in our trial will 
continue for up to five years, the primary outcome 
was deliberately assigned to the visit after 12 weeks, 
because patients expect an outcome of a surgical 
intervention at this time.
Meaning of the study findings, unanswered 
questions, and future research
The findings of this study elucidate the efficacy 
and safety profile of PAE. Our findings provide 
valuable information regarding patient selection and 
counselling, and will be useful for designing further 
trials in this field.
Larger scale trials and long term follow-up data 
are needed before PAE is implemented as a routine 
treatment for BPH-LUTS. The large standard deviation 
in our trial emphasises that such trials should also 
include subgroup analyses to detect patients who 
benefit most from PAE, which was beyond the scope 
of our study. Future research should also focus on 
the technical aspects of PAE, to determine the most 
efficient and safe approach with this intervention. 
Further refinement of embolisation techniques might 
eventually enable an even greater treatment effect. 
Owing to its favourable side effect profile, trials 
comparing PAE with non-invasive treatments (such 
as 5α-reductase inhibitors or combined treatments of 
α-blockers and 5α-reductase inhibitors) seem to be 
reasonable.
conclusions
This study shows that PAE is a valuable alternative 
to TURP in the treatment of BPH-LUTS. PAE should 
be considered in patients in whom the indication for 
surgery is primarily based on symptoms. For severe 
complications related to benign prostatic hyperplasia, 
TURP should be preferred. Further comparative study 
findings including longer follow-up periods and 
subgroup analyses should be evaluated before PAE can 
be considered as a routine treatment.
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